Ramm Pharma Corp

As of April 30, 2026, Ramm Pharma Corp carries a market capitalization of 1.79M, placing it among publicly traded companies globally. Its enterprise value stands at 1.72M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of April 30, 2026, Ramm Pharma Corp has 119.39M shares outstanding.

These figures are as of April 30, 2026. The price-to-sales ratio is 0.96, and the price-to-book ratio stands at 0.41.

These figures are as of April 30, 2026. The EV/Sales ratio of 0.92 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.72M versus a market cap of 1.79M, with the gap driven by net debt and cash on the balance sheet.

As of April 30, 2026, Ramm Pharma Corp maintains a current ratio of 0.47, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.02, indicating moderate leverage, while an interest coverage ratio of -13.89 demonstrates limited ability to service its debt obligations.

Over the twelve months ended April 30, 2026, Ramm Pharma Corp posted a negative return on equity (ROE) of -100.14, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -74.08, reflecting losses generated across the asset base. Inventory turnover of 0.56 indicates how many times Ramm Pharma Corp sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended April 30, 2026, Ramm Pharma Corp recorded 104,533.00 in income tax expense. The company reported a pretax loss of -8.30M and -8.40M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 20, 2026, Ramm Pharma Corp's stock has declined approximately 66.67% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.03.

Over the twelve months ended April 30, 2026, Ramm Pharma Corp generated 1.87M in revenue and converted that into -8.40M in net income, yielding earnings per share of -0.07. EBITDA reached -3.33M, while operating income came in at -3.89M.

As of April 30, 2026, Ramm Pharma Corp holds 119,546.00 in cash and equivalents against 44,171.00 in total debt, resulting in a net debt position of -119,546.00. Total book value stands at 4.35M, with working capital of -1.46M providing operational flexibility.

Ramm Pharma Corp produced -1.84M in operating cash flow over the twelve months ended April 30, 2026. After subtracting 25,000.00 in capital expenditures, free cash flow totaled -1.82M - equivalent to -0.02 per share.

Over the twelve months ended April 30, 2026, Ramm Pharma Corp posted a gross margin of 59.13, reflecting its pricing power and cost economics. The operating margin of -207.78 and net profit margin of -449.07 provide insight into operational efficiency.

Over the twelve months ended April 30, 2026, Ramm Pharma Corp paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -101.43: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 5.68, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Ramm Pharma Corp shareholders.

As of April 30, 2026, Ramm Pharma Corp has an Altman Z-Score of -16.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.